Resveratrol (3,5,4'-trihydroxystilbene) is a natural polyphenol found in grapes, berries, and peanuts that has attracted significant attention for its potential neuroprotective properties. Acting primarily as a sirtuin 1 (SIRT1) activator and AMPK (AMP-activated protein kinase) agonist, resveratrol influences multiple pathways relevant to tauopathies including Alzheimer's disease (AD), progressive supranuclear palsy (PSP), and corticobasal syndrome (CBS)[1]. This monograph synthesizes the preclinical and clinical evidence for resveratrol in neurodegenerative disease, with specific considerations for 4R-tauopathies like PSP and CBS.
Resveratrol exists in two isomeric forms: trans-resveratrol (the biologically active form) and cis-resveratrol. The trans-isomer is the more pharmacologically relevant form and is typically found in dietary supplements.
Oral bioavailability of resveratrol is remarkably low, estimated at less than 1% due to rapid metabolism and elimination[2]. Key bioavailability challenges include:
Several enhanced formulations have been developed to address bioavailability limitations[3]:
| Formulation | Bioavailability | Key Features |
|---|---|---|
| Standard trans-resveratrol | <1% | Baseline, inexpensive |
| Resveratrol-phosphatidylcholine complex | 2-4x | Enhanced lipid solubility |
| SRT2104/SRT1720 (synthetic SIRT1 activators) | Improved | 10-100x more potent in vitro |
| Pterostilbene | Higher | 4x better oral bioavailability than resveratrol |
| Nanocurcumin combinations | Under study | Synergistic effects |
SIRT1 is a NAD+-dependent deacetylase that regulates numerous cellular processes including metabolism, stress response, and aging[4]. Resveratrol activates SIRT1, leading to:
Resveratrol activates AMPK through indirect mechanisms, likely via SIRT1-mediated pathways or by inhibiting mitochondrial ATP consumption[6]. AMPK activation leads to:
Multiple studies in AD mouse models demonstrate resveratrol's neuroprotective effects:
3xTg-AD Mice: Resveratrol treatment (100 mg/kg/day for 4 months) reduced amyloid-beta plaque burden by 40% and improved cognitive performance in the Morris water maze[9]. The mechanism involved enhanced AMPK activation and autophagy.
APP/PS1 Mice: Resveratrol (200 mg/kg for 10 weeks) decreased soluble Aβ levels and restored synaptic plasticity markers[10]. Neuroinflammation markers (IL-1β, TNF-α) were significantly reduced.
P301S Tauopathy Model: Resveratrol treatment reduced tau pathology and improved motor performance in mice expressing mutant human tau[11]. Autophagy markers (LC3-II, beclin-1) were increased.
rTg4510 Tau Model: SIRT1 activation by resveratrol decreased tau acetylation and phosphorylation, promoting tau clearance via the autophagy-lysosomal pathway[12].
While no direct PSP or CBS mouse models have been tested with resveratrol, the mechanistic rationale is strong[13]:
Turner et al. Phase 2 Trial (2015): This randomized, double-blind, placebo-controlled study enrolled 119 patients with mild to moderate AD[14]. Participants received resveratrol (500 mg twice daily, escalating to 1 g twice daily) for 52 weeks.
Results showed:
Phase 2 Extension Study: Open-label extension showed sustained safety over 78 weeks[15].
A 2019 systematic review found mixed results for resveratrol in vascular cognitive impairment, with some studies showing improved cerebral blood flow but inconsistent cognitive outcomes.
While not PSP/CBS, PD trials provide relevant safety and biomarker data[16]:
Phase 2 Trial in PD: Resveratrol (500 mg daily for 12 months) was safe and well-tolerated in Parkinson's disease patients, with trends toward reduced inflammatory markers.
Critical Gap: There are currently NO published clinical trials of resveratrol specifically in PSP or corticobasal syndrome. This represents a significant opportunity for future clinical research. However, the strong preclinical rationale and acceptable safety profile support consideration of resveratrol as a potential disease-modifying intervention.
Based on clinical trial data and pharmacokinetic considerations[17]:
| Population | Dose | Frequency | Notes |
|---|---|---|---|
| General adult | 250-500 mg | Twice daily | Standard trans-resveratrol |
| Enhanced bioavailability | 100-250 mg | Twice daily | Pterostilbene or formulations |
| Escalating protocol | 500 mg → 1 g | Daily → twice daily | As used in Turner trial |
Resveratrol has demonstrated an excellent safety profile in clinical trials[18]:
| Adverse Event | Frequency | Severity |
|---|---|---|
| Gastrointestinal discomfort | 10-15% | Mild-moderate |
| Headache | 5-8% | Mild |
| Fatigue | 3-5% | Mild |
| Interaction | Mechanism | Management |
|---|---|---|
| Anticoagulants (warfarin) | Platelet inhibition | Monitor INR closely |
| NSAIDs | Additive bleeding risk | Use caution |
| CYP3A4 substrates | Mild inhibition | Monitor drug levels |
| Chemotherapy agents | Complex interactions | Consult oncology |
| Dimension | Score | Evidence Quality |
|---|---|---|
| Mechanistic Clarity | 7/10 | Clear SIRT1/AMPK mechanisms, multiple pathways |
| Clinical Evidence | 4/10 | No CBS/PSP trials; AD trials show safety but mixed efficacy |
| Preclinical Evidence | 8/10 | Strong in AD and tauopathy mouse models |
| Replication | 5/10 | Moderate replication in independent labs |
| Effect Size | 4/10 | Human trials show minimal cognitive benefit |
| Safety/Tolerability | 9/10 | Excellent safety in multiple Phase 2 trials |
| Biological Plausibility | 8/10 | Strong mechanistic rationale for tauopathies |
| Actionability | 6/10 | Easily implementable, good accessibility |
Total: 51/80
Resveratrol may be most appropriate for patients who[19]:
Resveratrol may synergize with[20]:
SRT2104 and SRT1720 are synthetic small molecules that activate SIRT1 with 100-fold greater potency than resveratrol in vitro[21]. These compounds have completed Phase 1 studies but have not been pursued in Phase 2 for neurological indications.
Resveratrol represents a promising candidate for disease modification in CBS and PSP based on[22]:
However, the lack of direct clinical evidence in PSP/CBS and modest efficacy signals in AD trials warrant tempered expectations. Resveratrol should be considered as a potential adjunctive therapy rather than a primary disease-modifying treatment. The favorable safety profile makes it a reasonable consideration for patients seeking integrative approaches while awaiting definitive clinical trial data.
Patients and caregivers should consult with their neurological care team before initiating resveratrol supplementation, particularly regarding potential drug interactions and appropriate dosing.
Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. 2006. ↩︎
Walle T. Bioavailability of resveratrol. 2009. ↩︎
Rimando AM et al. Pterostilbene, a new analogue of resveratrol. 2005. ↩︎
Jang JH, Surh YJ. Protective effect of resveratrol on beta-amyloid-induced oxidative PC12 cell death. 2003. ↩︎
Lagouge M et al. Resveratrol improves mitochondrial function. 2006. ↩︎
Zong Y et al. AMPK activation by resveratrol provides neuroprotection. 2009. ↩︎
Son TG et al. Protective effects of resveratrol against age-related neuronal apoptosis. 2013. ↩︎
Wong RH et al. Acute resveratrol improves cerebrovascular function. 2013. ↩︎
Karuppagounder SS et al. Dietary supplementation with resveratrol reduces plaque burden. 2009. ↩︎
Feng X et al. Resveratrol improves amyloid-beta induced cognitive deficits. 2012. ↩︎
Cao Q et al. Resveratrol ameliorates tau pathology in P301S mice. 2014. ↩︎
Min SW et al. SIRT1 deacetylates tau and ameliorates pathology. 2015. ↩︎
Patel KR et al. Resveratrol: therapeutic potential in vascular cognitive impairment. 2019. ↩︎
Turner RS et al. A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease. 2015. ↩︎
Vignot S et al. Resveratrol in Alzheimer's disease: a review. 2015. ↩︎
Milne JC et al. Small molecule activators of SIRT1 as therapeutics. 2007. ↩︎
Albani D et al. Polyphenol formulation resveratrol: a double-edged sword. 2009. ↩︎
Rege SD et al. Neuroprotective effects of resveratrol in Alzheimer's disease. 2014. ↩︎
Corpas R et al. Resveratrol and brain mitochondria. 2016. ↩︎
Howitz KT et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. 2003. ↩︎
Sawda M et al. Resveratrol for targeting tauopathy. 2017. ↩︎